Oncology News | pharmaphorum

News

Cancer Research UK earmarks £123m for Scottish R&D

Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th

News

Menarini brings oral SERD to Europe with Orserdu okay

Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

News

Novartis returns PD-1 antibody rights to BeiGene

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rig

News

GSK gets wide FDA approval for myelofibrosis drug

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire

Cancer Research UK earmarks £123m for Scottish R&D

Menarini brings oral SERD to Europe with Orserdu okay

Roche inks pipeline deals with Orionis, PeptiDream

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

Novartis returns PD-1 antibody rights to BeiGene

GSK gets wide FDA approval for myelofibrosis drug

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks